Your session is about to expire
← Back to Search
Tabelecleucel for Post-Transplant Cancer (ALLELE Trial)
ALLELE Trial Summary
This trial will test the safety and effectiveness of a new treatment for a type of cancer that can occur after organ transplantation.
ALLELE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowALLELE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ALLELE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the United States Food and Drug Administration given its okay to tabelecleucel?
"There is existing clinical data that tabelecleucel is safe for use, thus it received a score of 3."
Are there any current openings for patients who wish to enroll in this clinical trial?
"According to the website clinicaltrials.gov, this study is looking for more participants and was last updated on 6/23/2022."
How many people are taking part in this research project?
"The trial sponsor, Atara Biotherapeutics, needs to enroll 66 eligible patients from multiple locations including Alberta Children's Hospital (Adults and Pediatrics) in Calgary, Alberta and UCLA Medical Center (Adults and Pediatrics) in Los Angeles, California."
Is this research project being undertaken in multiple places across North America?
"Enrollment for this clinical trial is still open at 32 sites. These locations include cities such as Calgary, Los Angeles and Durham. If you are considering participating in this trial, please select the location nearest to you in order to reduce travel-related stressors."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger